Is Your Compounded Semaglutide Safe? Understanding Salt Forms, COAs, and the 2026 Regulatory Shift
Millions of people rely on compounded semaglutide as a more affordable alternative to brand-name GLP-1 medications. But as the FDA intensifies enforcement actions in 2026, a critical question has emerged: is the compounded semaglutide you're using actually the same molecule as the FDA-approved drug? The answer, in many cases, is more complicated than most patients realize.
This guide breaks down the science behind semaglutide salt forms, explains the legal framework governing compounding pharmacies, and provides a practical checklist for evaluating the quality and legitimacy of any compounded peptide product — including what to look for in a Certificate of Analysis (COA).
The Salt Form Problem: Semaglutide Base vs. Semaglutide Sodium
At the heart of the 2026 compounded semaglutide controversy is a chemistry distinction that most patients have never heard of: the difference between semaglutide base (the FDA-approved active pharmaceutical ingredient) and semaglutide sodium (a salt form used by some compounding pharmacies).
What Is a Salt Form?
In pharmaceutical chemistry, a "salt form" is created when an active drug molecule is combined with an acid or base to improve its stability, solubility, or shelf life. The resulting compound has a different molecular structure and weight than the original molecule. While salt forms are common in pharmaceuticals — and many are perfectly safe — the critical issue is that a salt form is not the same as the original molecule.
FDA-approved semaglutide (found in Ozempic, Wegovy, and Rybelsus) uses semaglutide base as its active ingredient. Some compounding pharmacies, however, have been sourcing and using semaglutide sodium — a salt form that has never been independently tested for safety or efficacy in humans at therapeutic doses.
Why Does This Matter?
The FDA has explicitly stated that semaglutide sodium is not an approved active pharmaceutical ingredient. This means:
- No established dosing equivalence: A 1 mg dose of semaglutide sodium does not necessarily deliver the same amount of active semaglutide as 1 mg of semaglutide base. The molecular weight difference means patients may be receiving more or less active drug than intended.
- No human safety data: The clinical trials that established semaglutide's safety and efficacy profile were conducted using the base form. The sodium salt has not undergone equivalent human testing.
- Unknown impurity profiles: Different manufacturing processes for salt forms can introduce different impurity profiles, which may carry unknown risks.
- Legal exposure for pharmacies: Compounding pharmacies using unapproved bulk drug substances — including semaglutide sodium — are operating outside the legal framework established by the FDA, exposing both the pharmacy and the patient to significant risk.
The FDA issued warning letters to multiple compounding pharmacies in 2024 and 2025 specifically citing the use of semaglutide sodium as a violation of federal law. In 2026, enforcement has intensified significantly as the FDA declared the official shortage of semaglutide resolved.
Understanding the Legal Framework: 503A vs. 503B Pharmacies
Not all compounding pharmacies operate under the same rules. The Drug Quality and Security Act (DQSA) of 2013 created two distinct categories of compounding pharmacies, and understanding the difference is essential for anyone using compounded peptides.
503A Pharmacies: Traditional Compounders
503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed practitioner. Key characteristics include:
- Must compound based on a patient-specific prescription
- Regulated primarily by state pharmacy boards
- Can only compound drugs that are not commercially available or that require customization for a specific patient's needs
- Are not required to register with the FDA or comply with Current Good Manufacturing Practice (CGMP) regulations
- Cannot compound copies of commercially available drugs unless there is a documented clinical difference
503B Outsourcing Facilities: Higher-Standard Compounders
503B outsourcing facilities are a newer category created specifically to allow larger-scale compounding for healthcare facilities. They operate under significantly stricter standards:
- Must register with the FDA and are subject to FDA inspection
- Must comply with CGMP regulations — the same manufacturing standards applied to pharmaceutical manufacturers
- Can produce larger batches without patient-specific prescriptions
- Are subject to more rigorous testing and quality control requirements
- Products must meet stricter labeling and documentation standards
From a safety standpoint, a compounded semaglutide product from a registered 503B outsourcing facility that uses verified semaglutide base and complies with CGMP standards represents a meaningfully different risk profile than a product from an unregistered 503A pharmacy using semaglutide sodium sourced from an overseas bulk supplier.
The 2026 Regulatory Landscape: What Changed and Why It Matters
The widespread availability of compounded semaglutide was largely enabled by the FDA's official designation of semaglutide as a drug in shortage. Under federal law, compounding pharmacies are permitted to compound copies of commercially available drugs when those drugs are on the FDA's drug shortage list. This legal pathway allowed thousands of compounding pharmacies to legally produce semaglutide products during the shortage period.
The Shortage Resolution and Its Consequences
In early 2025, the FDA announced that the shortage of semaglutide injection products had been resolved. This declaration had immediate and significant legal consequences for compounding pharmacies:
- The primary legal justification for compounding copies of semaglutide was eliminated
- 503A pharmacies lost the ability to compound semaglutide for most patients
- 503B facilities were given a limited wind-down period to cease production
- Pharmacies continuing to compound semaglutide after the wind-down period became subject to FDA enforcement action
The FDA has since issued numerous warning letters and taken enforcement actions against pharmacies continuing to compound semaglutide without legal justification. In 2026, this enforcement has expanded to include civil and criminal referrals in the most egregious cases.
The Narrow Exceptions That Remain
It is important to note that some legitimate pathways for compounded semaglutide still exist in 2026, though they are narrow:
- Documented patient-specific need: A 503A pharmacy may still compound semaglutide for a patient who has a documented allergy to an inactive ingredient in the commercial product, or who requires a specific dose or formulation not commercially available.
- Tirzepatide shortage: As of mid-2026, tirzepatide remains on the FDA shortage list in some dosage strengths, meaning compounded tirzepatide may still be legally available through compliant pharmacies.
- Research contexts: Peptides obtained for legitimate research purposes operate under a different regulatory framework than those intended for human therapeutic use.
How to Evaluate a Compounded Peptide: The COA Checklist
A Certificate of Analysis (COA) is a document issued by a testing laboratory that certifies the identity, purity, and potency of a chemical compound. For anyone working with research peptides, understanding how to read and evaluate a COA is an essential skill.
What a Legitimate COA Should Include
A high-quality COA for a research peptide should contain the following elements:
- Identity confirmation: Results from High-Performance Liquid Chromatography (HPLC) or Mass Spectrometry (MS) confirming the compound's molecular identity. For semaglutide, this should confirm the base form, not a salt form.
- Purity percentage: HPLC purity should ideally be ≥98% for research-grade peptides. Lower purity indicates the presence of impurities or degradation products.
- Potency/concentration: Confirmation that the stated concentration matches the actual concentration in the product.
- Sterility testing: For injectable peptides, evidence of sterility testing (absence of bacterial contamination) is critical.
- Endotoxin testing: Bacterial endotoxins (pyrogens) can cause severe inflammatory reactions when injected. A legitimate COA should include endotoxin testing results.
- Testing laboratory information: The name, accreditation, and contact information of the independent third-party laboratory that performed the testing. The lab should be ISO/IEC 17025 accredited.
- Lot number and date: The COA should be specific to the lot number of the product you received, not a generic document.
Red Flags in a COA
Be cautious of any COA that:
- Does not specify the testing laboratory or lists an unaccredited lab
- Shows purity below 95%
- Does not include endotoxin or sterility testing for injectable products
- Cannot be matched to a specific lot number
- Identifies the compound as a salt form (e.g., "semaglutide sodium") rather than the base
- Is undated or uses a generic template that appears to apply to multiple products
Reputable research peptide suppliers like Progressing (cpwt.shop) provide lot-specific COAs from accredited third-party laboratories for their research peptide catalog, allowing researchers to verify the identity and purity of compounds before use.
Reconstitution and Storage: Safety Considerations for Research Peptides
Beyond sourcing and documentation, proper handling of lyophilized (freeze-dried) peptides is critical for maintaining their integrity and safety in research contexts.
Bacteriostatic Water vs. Sterile Water
Most research peptides are supplied in lyophilized powder form and must be reconstituted with a liquid before use. The two most common options are:
- Bacteriostatic water (BAC water): Sterile water containing 0.9% benzyl alcohol, which acts as a preservative. BAC water allows a reconstituted peptide solution to be stored for up to 28 days when refrigerated. It is the preferred choice for most research peptides.
- Sterile water for injection: Pure sterile water without preservatives. Reconstituted solutions should be used within 24 hours and cannot be stored for extended periods.
Storage Best Practices
Peptides are sensitive molecules that can degrade rapidly if not stored correctly:
- Lyophilized peptides: Store at -20°C (freezer) for long-term storage, or at 2-8°C (refrigerator) for short-term use (up to several weeks). Protect from light.
- Reconstituted peptides: Store at 2-8°C. Never freeze a reconstituted peptide solution, as ice crystal formation can damage the peptide structure.
- Avoid repeated freeze-thaw cycles: Each freeze-thaw cycle degrades peptide integrity. If you have a large quantity, consider aliquoting into single-use vials before freezing.
- Minimize exposure to air: Oxidation can degrade certain peptides. Use proper vial sealing techniques and minimize the time vials are open.
The Broader Research Context: Why These Distinctions Matter
The regulatory and quality issues surrounding compounded semaglutide are not isolated to a single drug — they reflect broader challenges in the research peptide landscape. As interest in peptide science continues to grow, the gap between rigorous pharmaceutical-grade research and unregulated consumer products has become a significant concern for researchers, clinicians, and regulators alike.
Understanding the difference between a 503A and 503B pharmacy, knowing how to read a COA, and recognizing the significance of salt form distinctions are not just regulatory technicalities — they are fundamental to conducting safe and scientifically valid research. The same principles that apply to compounded semaglutide apply equally to other research peptides: source matters, documentation matters, and chemistry matters.
As the regulatory environment continues to evolve in 2026 and beyond, researchers and clinicians who invest in understanding these distinctions will be better positioned to navigate the landscape safely and effectively. Always consult with a qualified healthcare professional or regulatory expert before making decisions about peptide use in any context.
Key Takeaways
- Semaglutide sodium is not the same as FDA-approved semaglutide base, and its use in compounded products raises significant safety and legal concerns.
- 503B outsourcing facilities operate under stricter FDA oversight than 503A pharmacies and generally represent a higher standard of quality for compounded products.
- The resolution of the FDA semaglutide shortage in 2025 eliminated the primary legal justification for most compounded semaglutide, and enforcement has intensified in 2026.
- A legitimate COA from an accredited third-party laboratory is an essential quality verification tool for any research peptide.
- Proper reconstitution and storage practices are critical for maintaining peptide integrity and safety in research contexts.
- When in doubt, consult a healthcare professional or regulatory expert — the stakes of using an impure, misdosed, or legally questionable compound are too high to ignore.